Skip to content
Search

Latest Stories

Sajid Javid gets flu jab in London pharmacy

Health secretary Sajid Javid had his seasonal influenza vaccine administered at a community pharmacy in London today (Oct 12).

“I’ve done my bit by getting my flu vaccine," Javid said, after receiving his vaccine at Keencare Pharmacy, part of the Green Light Pharmacy group and a National Pharmacy Association (NPA) member.


The health secretary called upon those eligible to "come forward for both their flu and Covid-19 booster vaccines" to protect themselves and their loved ones "in the months ahead".

Javid said: “Alongside the Covid-19 booster jabs, we are rolling out the biggest flu programme in our history, with a record 35 million people in England eligible for a free flu jab to keep them safe this winter."

The visit was organized by the NPA and the Department of Health and Social Care.

Stating how it was "great" to have hosted Javid "at our pharmacy and vaccinate him against flu", pharmacist Cynthia Langworthy said the health secretary "recognized" the efforts of community pharmacy during the pandemic and "was very appreciative" of the key role played by the sector in the NHS.

sajid javid flu jab Pharmacist Cynthia Langworthy gives Sajid Javid his flu jab. Photo: NPA

She added that they "spoke about the wide range of services pharmacies provide" and discussed "how pharmacy is often the ‘front door’ of the NHS for many of our patients.”

NPA chair Andrew Lane, who was also present on the occasion, handed the health secretary a copy of the NPA’s How We Can Help report.

Lane said: “We are delighted to have helped arrange for NPA member Green Light Pharmacy to vaccinate the health secretary against flu.

“It also gave us the opportunity to have an initial conversation with him about how pharmacies can help meet the backlog challenge facing the NHS.”

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less